SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Elbaz David)
 

Sökning: WFRF:(Elbaz David) > Treatment Outcomes ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007798naa a2200997 4500
001oai:DiVA.org:uu-394059
003SwePub
008191002s2019 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3940592 URI
0247 a https://doi.org/10.1093/cid/ciy9882 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Dickstein, Yaakovu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel4 aut
2451 0a Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections :b An Exploratory Subgroup Analysis of a Randomized Clinical Trial
264 c 2018-11-20
264 1b OXFORD UNIV PRESS INC,c 2019
338 a print2 rdacarrier
520 a Background We evaluated the association between mortality and colistin resistance in Acinetobacter baumannii infections and the interaction with antibiotic therapy. Methods This is a secondary analysis of a randomized controlled trial of patients with carbapenem-resistant gram-negative bacterial infections treated with colistin or colistin-meropenem combination. We evaluated patients with infection caused by carbapenem-resistant A. baumannii (CRAB) identified as colistin susceptible (CoS) at the time of treatment and compared patients in which the isolate was confirmed as CoS with those whose isolates were retrospectively identified as colistin resistant (CoR) when tested by broth microdilution (BMD). The primary outcome was 28-day mortality. Results Data were available for 266 patients (214 CoS and 52 CoR isolates). Patients with CoR isolates had higher baseline functional capacity and lower rates of mechanical ventilation than patients with CoS isolates. All-cause 28-day mortality was 42.3% (22/52) among patients with CoR strains and 52.8% (113/214) among patients with CoS isolates (P = .174). After adjusting for variables associated with mortality, the mortality rate was lower among patients with CoR isolates (odds ratio [OR], 0.285 [95% confidence interval {CI}, .118-.686]). This difference was associated with treatment arm: Mortality rates among patients with CoR isolates were higher in those randomized to colistin-meropenem combination therapy compared to colistin monotherapy (OR, 3.065 [95% CI, 1.021-9.202]). Conclusions Colistin resistance determined by BMD was associated with lower mortality among patients with severe CRAB infections. Among patients with CoR isolates, colistin monotherapy was associated with a better outcome compared to colistin-meropenem combination therapy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a Acinetobacter
653 a carbapenem-resistant
653 a colistin
653 a gram-negative bacteria
653 a XDR-TB
7001 a Lellouche, Jonathanu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 aut
7001 a Amar, Maayan Ben Dalaku Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 aut
7001 a Schwartz, Davidu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 aut
7001 a Nutman, Amiru Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel4 aut
7001 a Daitch, Veredu Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel;Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel4 aut
7001 a Yahav, Dafnau Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel;Beilinson Med Ctr, Rabin Med Ctr, Unit Infect Dis, Petah Tiqwa, Israel4 aut
7001 a Leibovici, Leonardu Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel;Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel4 aut
7001 a Skiada, Annau Laikon Gen Hosp, Dept Med 1, Athens, Greece;Univ Athens, Athens, Greece4 aut
7001 a Antoniadou, Anastasiau Univ Athens, Athens, Greece;Attikon Univ Gen Hosp, Dept Med 4, Athens, Greece4 aut
7001 a Daikos, George L.u Laikon Gen Hosp, Dept Med 1, Athens, Greece;Univ Athens, Athens, Greece4 aut
7001 a Andini, Robertou Univ Campania L Vanvitelli, Dept Precis Med, Naples, Italy;Azienda Osped Rilievo Nazl Colli Monaldi Hosp, Naples, Italy4 aut
7001 a Zampino, Rosau Univ Campania L Vanvitelli, Dept Precis Med, Naples, Italy;Azienda Osped Rilievo Nazl Colli Monaldi Hosp, Naples, Italy4 aut
7001 a Durante-Mangoni, Emanueleu Univ Campania L Vanvitelli, Dept Precis Med, Naples, Italy;Azienda Osped Rilievo Nazl Colli Monaldi Hosp, Naples, Italy4 aut
7001 a Mouton, Johan W.u Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands4 aut
7001 a Friberg, Lenau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo
7001 a Benattar, Yael Dishonu Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel;Univ Haifa, Cheryl Spencer Dept Nursing, Haifa, Israel4 aut
7001 a Bitterman, Roniu Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel4 aut
7001 a Neuberger, Amiu Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel4 aut
7001 a Carmeli, Yehudau Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel;Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel4 aut
7001 a Paul, Micalu Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel;Technion Israel Inst Technol, Fac Med, Haifa, Israel4 aut
7001 a Zayyad, Hiba4 aut
7001 a Koppel, Fidi4 aut
7001 a Zak-Doron, Yael4 aut
7001 a Altunin, Sergey4 aut
7001 a Andria, Nizar4 aut
7001 a Stern, Anat4 aut
7001 a Petersiel, Neta4 aut
7001 a Raines, Marina4 aut
7001 a Karban, Amir4 aut
7001 a Eliakim-Raz, Noa4 aut
7001 a Zusman, Oren4 aut
7001 a Elbaz, Michal4 aut
7001 a Atamna, Heyam4 aut
7001 a Babich, Tanya4 aut
7001 a Adler, Amos4 aut
7001 a Levi, Inbar4 aut
7001 a Pavleas, Ioannis4 aut
7001 a Kotsaki, Antigoni4 aut
7001 a Iossa, Domenico4 aut
7001 a Bernardo, Mariano4 aut
7001 a Cavezza, Giusi4 aut
7001 a Bertolino, Lorenzo4 aut
7001 a Giuffre, Giuseppe4 aut
7001 a Giurazza, Roberto4 aut
7001 a Cuccurullo, Susanna4 aut
7001 a Galdo, Maria4 aut
7001 a Murino, Patrizia4 aut
7001 a Cristinziano, Adriano4 aut
7001 a Corcione, Antonio4 aut
7001 a Pafundi, Pia Clara4 aut
7001 a Mouton, Johan4 aut
7001 a Friberg, Lena4 aut
7001 a Kristoffersson, Anders4 aut
7001 a Theuretzbacher, Ursula4 aut
7102 a Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israelb Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel;Tel Aviv Sourasky Med Ctr, Mol Epidemiol Lab, Tel Aviv, Israel4 org
7730 t Clinical Infectious Diseasesd : OXFORD UNIV PRESS INCg 69:5, s. 769-776q 69:5<769-776x 1058-4838x 1537-6591
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-394059
8564 8u https://doi.org/10.1093/cid/ciy988

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy